Rentschler Biopharma is a global contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals and therapies. Headquartered in Laupheim, Germany, with sites in Milford, MA, USA, and Stevenage, UK, the company contributed to nearly 25% of new biopharmaceuticals approved by the FDA in 2023. The Milford site has expanded to include a new 22,000 sq. ft. manufacturing suite, doubling the company's cGMP capacity. This site focuses on complex molecule production for international clients and recently secured a major client for an innovative cancer therapeutic. Rentschler Biopharma’s commitment to advancing medicine and community involvement earned it the Gold MassEcon Impact Award.
Visit Company Website
